Skip to main content
. 2010 Aug 23;31(9):1189–1197. doi: 10.1038/aps.2010.150

Figure 4.

Figure 4

In vitro and in vivo antitumor activities of ZSTK474. (A) Fingerprint of ZSTK474 for the JFCR39 panel9. Fingerprint indicates the differential growth inhibition pattern of ZSTK474 for the cell lines in JFCR39 panel. The X-axis shows difference in logarithmic scale between the mean of Log GI50 values for all 39 cell lines (MG-MID, expressed as 0 in the fingerprint) and the Log GI50 for each cell line in JFCR39 panel. Columns to the right of 0 indicate the sensitivity of the cell lines to a given compound and columns to the left indicate the resistance. MG-MID=mean of Log GI50 values for all 39 cell lines; Delta=difference between the MG-MID and the Log GI50 value for the most sensitive cell line; Range=difference between the Log GI50 values for the most resistant cell line and the most sensitive cell line. (B) In vitro antiangiogenic effect of ZSTK474. Upper panel: Wound healing assay shows ZSTK474 potently inhibits migration of HUVECs at 1 μmol/L; lower panel: ZSTK474 potently blocks the in vitro tube formation by HUVECs67. (C) In vivo antitumor efficacy of ZSTK474. Oral administration of ZSTK474 at 400 mg/kg to WiDr xenograft daily from day 0 to 26, except for days 6, 13, and 20, lead to obvious tumor growth inhibition. The pictures were taken on day 2811.